Low Testosterone Treatment News: Wright & Schulte LLC Notes Possible Alternative to Currently Approv

FDA Reviewing the Safety of AndroGel and Other Approved Low Testosterone Treatments after Studies Linked Their Use to a Higher Risk of Heart Attacks, Strokes and Death in Certain Men Columbus, OH (PRWEB) October 07, 2014 As concerns surrounding the cardiovascular side effects of AndroGel and other currently approved low testosterone treatments continue to grow, Wright & Schulte LLC notes that one pharmaceutical company is positioning its experimental medication as a superior alternative to these drugs. According to a report from Reuters, Repros Therapeutics Inc. recently announced that
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories